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Brain dopamine is critically involved in movement control, and its deficiency is the primary cause of motor symptoms
in Parkinson disease. Here we report development of an animal model of acute severe dopamine deficiency by using
mice lacking the dopamine transporter. In the absence of transporter-mediated recycling mechanisms, dopamine
levels become entirely dependent on de novo synthesis. Acute pharmacological inhibition of dopamine synthesis in
these mice induces transient elimination of striatal dopamine accompanied by the development of a striking
behavioral phenotype manifested as severe akinesia, rigidity, tremor, and ptosis. This phenotype can be reversed by
administration of the dopamine precursor, L-DOPA, or by nonselective dopamine agonists. Surprisingly, several
amphetamine derivatives were also effective in reversing these behavioral abnormalities in a dopamine-independent
manner. Identification of dopamine transporter- and dopamine-independent locomotor actions of amphetamines
suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs.
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Introduction
The phenylethylamine derivative dopamine (DA) is crit-
ically involved in a wide variety of vital functions such as
locomotion, feeding, emotion, and reward [1–3]. Major DA
systems in the brain originate from brainstem DA neurons
located in the substantia nigra pars compacta (SNc) and the
ventral tegmental area (VTA). SNc neurons project mainly to
the caudate/putamen or dorsal striatum (nigrostriatal system),
whereas VTA neurons send their axons to the ventral
striatum including the nucleus accumbens, as well as certain
other limbic (mesolimbic system) and cortical areas (meso-
cortical system). Small DA-containing cell groups located
primarily in the hypothalamus comprise the tuberoinfundib-
ular DA system [4–6]. DA is synthesized from tyrosine by the
rate-limiting enzyme tyrosine hydroxylase (TH), to produce
L-DOPA which is quickly decarboxylated by L-aromatic acid
decarboxylase (L-AADC) to DA [1,3]. Intraneuronal DA is
accumulated into synaptic vesicles by the vesicular mono-
amine transporter-2 (VMAT2) [7,8]. DA released into the
extracellular space exerts its physiological functions via
activation of G protein-coupled D1-like and D2-like DA
receptors [9]. Finally, DA in the extracellular space is subject
to dilution by diffusion and metabolic degradation; however
the major route of DA clearance from the extracellular space
in the striatum/nucleus accumbens is the rapid recycling of
the neurotransmitter back into dopaminergic terminals by
the Na
þ/Cl
 –dependent plasma membrane dopamine trans-
porter (DAT) [10,11]. Recycled DA in the dopaminergic
terminals is then stored in the large intracellullar storage
pool available for subsequent re-release [12,13] .
It is well established that DA neurotransmission in both
dorsal and ventral striatum is essential for normal locomotor
functions, and progressive degeneration of DA neurons in
these areas is a known cause of Parkinson disease (PD). In
most cases, PD becomes clinically apparent when the loss of
dopaminergic neurons reaches 60%–70%, which leads to
functional dysregulation of the related neuronal circuitry
[14–17]. Major motor manifestations of DA deﬁciency in PD
include, but are not limited to, resting tremor (tremor
occurring in the absence of voluntary movement), rigidity
(tonically increased muscle tone), bradykinesia/akinesia (slow-
ness/difﬁculty in initiating movement), gait disturbance and
postural instability, facial masking, and decreased eye-
blinking [18]. Presently, there is no known cure for PD
[19,20], however its symptoms can be controlled by ther-
apeutic interventions [21]. DA replacement therapy by
administration of the DA precursor, L-DOPA, has been used
for many years and remains the gold standard for treatment
of PD [22,23]. However, the efﬁcacy of this treatment wanes
with time, and ﬂuctuations in motor performance as well as
Received April 6, 2005; Accepted June 3, 2005; Published August 2, 2005
DOI: 10.1371/journal.pbio.0030271
Copyright:  2005 Sotnikova et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Abbreviations: 5-HT, serotonin; aMT, a-methyl-p-tyrosine; DA, dopamine; DAT,
dopamine transporter; DAT-KO mice, dopamine transporter knockout mice; DD
mice, dopamine-deficient mice; DDD mice, dopamine-deficient DAT-KO mice; IP,
intraperitoneal; L-AADC, L-aromatic acid decarboxylase; MAO, monoamine oxidase;
NE, norepinephrine; NET, norepinephrine transporter; PD, Parkinson disease; SC,
subcutaneous; SNc, Substantia Nigra Pars Compacta; TA1 receptor, trace amine 1
receptor; TH, tyrosine hydroxylase; VMAT2, vesicular monoamine transporter-2;
VTA, ventral tegmental area; WT, wild-type
Academic Editor: Eric Nestler, University of Texas Southwestern Medical Center,
United States of America
*To whom correspondence should be addressed. E-mail: caron002@mc.duke.edu
PLoS Biology | www.plosbiology.org August 2005 | Volume 3 | Issue 8 | e271 1488
Open access, freely available online PLoS BIOLOGYpsychotic reactions and dyskinesias often develop. DA
agonists, as well as several other classes of drugs directly or
indirectly affecting DA function (monoamine oxidase [MAO]
inhibitors, COMT [catechol-o-methyl transferase] inhibitors,
and amantadine), have some beneﬁcial effects in PD patients,
but they are mostly used either at early stages of PD or are
applied as adjunct medications to enhance the beneﬁts of L-
DOPA [21,24,25]. Due to these limitations of existing
therapeutic approaches, the development of better anti-
Parkinsonian drugs remains a major objective of PD research.
Several lines of evidence suggest that development of novel
non-dopaminergic approaches aimed at bypassing impaired
dopaminergic transmission would be beneﬁcial in PD,
particularly at later stages [16,26–28], however it is still
unclear if these treatments would just potentiate action of
residual DA or act completely independently of DA.
A number of animal models of DA deﬁciency, based on
pharmacologic, neurotoxic, or genetic approaches, have been
developed to understand basic pathological processes leading
to PD and/or to search for novel principles of therapy [29–36].
However, in rodents, the prolonged absence of DA is not
compatible with life [3,7,8], and animals with chronic severe
DA depletion are generally not available for routine
experimentation. We have developed mice lacking a func-
tional DAT (DAT-KO mice) [11] that display remarkable
alterations in the compartmentalization of DA [12,13,37].
Lack of the DAT-mediated inward transport in these mice
results in an elevated extracellular DA and at least 95%
decreased intracellular DA stores. Unlike normal animals,
these mice demonstrate remarkable dependence of the
remaining DA on ongoing synthesis, and pharmacologic
blockade of DA synthesis in DAT-KO mice provides an
effective approach to eliminate DA acutely [12,13].
Substituted phenylethylamine derivatives, amphetamines,
that are structurally similar to DA and the endogenous trace
amine b-phenylethylamine, represent a well-known group of
compounds that potently affect psychomotor functions.
Amphetamines are known to interact with plasma membrane
monoamine transporters, including DAT, norepinephrine
(NE) transporter (NET), and serotonin transporter. This
complex interaction results in transporter-dependent efﬂux
of monoamines into extracellular space from intraneuronal
stores [10,38,39]. It is commonly believed that DAT-mediated
efﬂux of DA is primarily responsible for the psychostimulant
and hyperlocomotor actions of these drugs [38,40,41]. Intrigu-
ingly, recent studies have identiﬁed novel transporter-inde-
pendent targets of amphetamines. It has been shown that
amphetamines, as well as b-phenylethylamine, some mono-
amine metabolites, and several drugs affecting monoaminer-
gic transmission, can directly activate speciﬁc G protein–
coupled trace amine (trace amine 1 [TA1]) receptors [42] with
currently unknown functional consequences [43,44].
We report here that the pharmacologic inhibition of the
rate-limiting enzyme of DA synthesis, TH, almost immedi-
ately depletes brain DA to undetectable levels in DAT-KO
mice and induces a transient recapitulation of essentially all
PD symptoms for up to 16 h. DA-deﬁcient DAT-KO mice
(DDD mice) thus represent an acute PD model that is useful
for studying the efﬁcacy of compounds that potentially can
restore control of locomotion in the absence of any
contribution of the dopaminergic system. By using this
approach, we found that several amphetamine derivatives
can counteract the behavioral manifestations of severe DA
deﬁciency, suggesting that, in addition to well-known DA-
mediated effects, amphetamine-like compounds can also
affect motor functions in a DA- and DAT-independent
manner.
Results
A Pharmacologic Approach for Provoking Selective DA
Deficiency in DAT-KO Mice
The ability of a-methyl-p-tyrosine (aMT), a potent irrever-
sible inhibitor of TH [29,45,46], to impede production of
brain DA suggests a simple, but straightforward, strategy for
producing an acute PD mouse model. However, numerous
studies have documented that treatment of normal animals
with aMT results only in a relatively slow and partial
depletion of DA in brain tissues that is not sufﬁcient for
generation of PD-like symptoms [29,45,46]. This limited
depletion is based upon how DA is stored. It is believed that
the large intraneuronal DA storage pool that normally exists
in striatal DA terminals provides sufﬁcient DA to release and
recycle back into releasing terminals up to the time when
newly synthesized TH starts to regain its functional role
[29,45,46]. Thus, in a normal animal, complete depletion of
striatal DA is unachievable by TH inhibition alone, and
additional depletion of vesicular DA by VMAT2 inhibitors,
such as reserpine is required [33,47–49]. Protocols designed
for wild-type [WT] mice that use a dual inhibitor strategy
(VMAT2 plus TH inhibitors) deplete DA to 1%–2% of
control levels [33,47–50], but the levels of other monoamine
neurotransmitters that are substrates for VMAT2 are also
severely affected. This nonselective targeting of monoami-
nergic signaling generally results in very complicated
phenotypes that are not necessarily reﬂective of classic PD.
In the absence of any pharmacologic treatment, the
intraneuronal vesicular stores of DA in the striatum of
DAT-KO mice are already profoundly depleted by at least
20-fold [12]. This selective depletion of DA in dopaminergic
terminals of DAT-KO mice, as well as analogous depletion
observed in mice lacking NET [51] or serotonin transporter
[52] with NE and serotonin (5-HT), respectively, reﬂects the
critical role of transporter-mediated recycling in the main-
tenance of intracellular storage pools [13]. With loss of the
major intracellular storage pool of DA in DAT-KO mice,
both the intracellular and extracellular levels of DA in the
striatum become critically dependent upon ongoing DA
synthesis. Therefore in DAT-KO mice, acute TH inhibition
alone by aMT is sufﬁcient to induce profound depletion of
DA [12,13,37].
To explore this phenomenon in detail, we ﬁrst measured
the time-course of striatal DA depletion in DAT-KO and
control mice following treatment with aMT (Figure 1). In
agreement with previous studies [13], we observed that in
saline-treated DAT-KO mice, striatal tissue levels of DA were
about 20-fold lower than in WT controls (Figure 1A). The
systemic administration of aMT (250 mg/kg IP) to DAT-KO
mice produced rapid (15 min) and virtually complete (down
to 5% of control levels in DAT-KO mice that is equivalent to
less than 0.2% of WT control levels) depletion of striatal DA.
In contrast, in WT mice the same treatment resulted in a
relatively slow (4 h) depletion of only 60% of striatal tissue
DA (Figure 1B). The duration of the depletion in DAT-KO
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related to the de novo synthesis of TH, occurs [29,45].
Notably, the rate of recovery of striatal DA levels was
approximately the same in WT and DAT-KO mice.
Because DA itself serves as a precursor for neuronal
production of NE in NE neurons, the inhibition of TH should
also impact NE production. To test the impact of TH
inhibition on the NE system, the frontal cortex tissue NE
concentrations were measured in WT and DAT-KO mice. As
opposed to the DAT, NET expression is not altered in DAT-
KO mice so that the storage pool, which is by far the
predominant reservoir of NE in NE-enriched regions such as
the frontal cortex, should not be signiﬁcantly altered in these
mutants. Accordingly, the levels of NE in the frontal cortex
tissue of saline-treated DAT-KO mice did not vary from that
of WT mice (Figure 1C). Furthermore, aMT (250 mg/kg IP)
treatment induced similar NE depletion in WT and DAT-KO
mice by about 60% in 8 h after treatment. Importantly, the
rates of partial NE depletion and recovery were almost
identical between WT and DAT-KO mice (Figure 1D). Thus,
TH inhibition in DAT-KO mice induces rapid severe
depletion of DA, but only partially and slowly affects NE,
indicating selectivity of this marked depletion to neurons
expressing the DAT.
In order to demonstrate that targeting of TH by aMT
depletes the functional extracellular pool of DA in living
animals, we measured extracellular levels of striatal DA in
freely moving mice by in vivo microdialysis. In agreement
with total tissue DA data, aMT treatment essentially elim-
inated extracellular DA levels in DAT-KO mice (Figure 1F),
whereas only a partial decrease was observed in WT mice.
(Figure 1E). Thus, both intracellular and extracellular DA
levels in the striatum of DAT-KO mice are critically depend-
ent upon ongoing synthesis.
DA Depletion in DAT-KO Mice Results in a Loss
of Motor Control
It is well known that DA plays a pivotal role in the control
of various aspects of locomotor behaviors. Severe depletion
of DA in aMT-treated DAT-KO mice results in a very speciﬁc
akinetic phenotype (Figure 2; see Video S1). The DA-depleted
DAT-KO mice (DDD mice) become akinetic almost immedi-
ately after treatment, in contrast to the essentially normal
motor function displayed by aMT-treated WT mice. More-
over, DDD mice develop extreme rigidity, body tremor, and
ptosis (droopy eyelids). These behaviors are evident on
several tests (Figure 3). Akinesia was assessed by evaluating
horizontal locomotor activity (Figure 3A and 3B) and by an
‘‘akinesia’’ test (Figure 3C); rigidity assessed by a catalepsy test
(Figure 3D), a ‘‘grasping’’ test (Figure 3E), and a ‘‘bracing’’ test
(Figure 3F); whereas tremor (Figure 3G) and ptosis (Figure
3H, see also Figure 2B) were visually determined [3,53–58].
These behaviors were analyzed in WT and DAT-KO mice for
4 h after a aMT treatment when depletion of DA is most
severe in DAT-KO mice but with relatively minor effect on
NE levels (see Figure 1). In all these measures DDD mice
differed signiﬁcantly from their WT littermates or saline-
treated controls. Importantly, these abnormal behaviors in
DDD mice, with the exception of ptosis, became maximal
during the 30- to 60-min period following aMT exposure,
thus correlating with the rate of DA depletion. Ptosis devel-
oped substantially later (Figure 3H), suggesting an additional
Figure 1. aMT Induces Severe DA Depletion in the Striatum of DAT-KO
Mice
(A) Tissue levels of DA in the striatum of saline-treated control WT and
DAT-KO mice (n ¼ 7 per group). Striatal levels of DA were significantly
lower in DAT-KO versus WT mice (p , 0.05, Student’s t-test).
(B)DynamicsoftheeffectofaMT(250mg/kgIP)onstriataltissueDAinWT
and DAT-KO mice (n¼5–8 per group). DA levels were significantly lower
versus control values at all the time points after aMT treatment in DAT-KO
mice and 2–24 hours after treatment in WT mice (p , 0.05, one-way
ANOVA followed by Dunnet’s multiple comparison test). The magnitude
of the effect was significantly different between genotypes from 1 to 16 h
after aMT injection (p , 0.05, two-tailed Mann-Whitney U test).
(C) Tissue levels of NE in the frontal cortex of saline-treated WT and DAT-
KO mice (n ¼ 7 per group).
(D) Dynamics of the effect of aMT (250 mg/kg IP) on tissue levels of NE in
the frontal cortex of WT and DAT-KO mice (n¼5–8 per group). NE levels
were significantly lower versus control values at time points 2–16 after
aMT treatment in DAT-KO mice and at 4–16 hours after treatment in WT
mice (p , 0.05, one-way ANOVA followed by Dunnet’s multiple
comparison test). The magnitude of the effect was not different between
genotypes at any time point after aMT injection (p . 0.05, two-tailed
Mann-Whitney U test).
(E) Effect of aMT on extracellular DA levels in the striatum of WT mice,
measured using in vivo microdialysis. Data are presented as a percentage
of the average level of DA measured in at least three samples collected
before the drug administration. (Saline, n ¼ 5; aMT, n ¼ 7). aMT
significantly decreased DA levels 60–180 min after treatment (p , 0.05,
two-tailed Mann-Whitney U test versus respective time points in saline-
treated controls).
(F) Effect of aMT on extracellular levels of DA in the striatum of DAT-KO
mice, measured by using in vivo microdialysis in freely moving mice.
Data are presented as a percentage of the average level of DA measured
in at least three samples collected before drug administration. (Saline, n
¼4; aMT, n¼6). aMT significantly decreased DA levels 20–180 min after
treatment (p , 0.05, two-tailed Mann-Whitney U test versus respective
time points in saline-treated controls). Analysis of area under curve
values for 120-min periods after drug administration revealed significant
difference between DAT-KO and WT groups (p , 0.05, two-tailed Mann-
Whitney U test). Note also that the basal extracellular levels of DA in DAT-
KO mice were significantly higher than in WT mice (predrug concen-
trations of DA in dialysates were: WT, 76 6 17 fmol/20 ll; DAT-KO, 340 6
63 fmol/20 ll).
DOI: 10.1371/journal.pbio.0030271.g001
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response [59]. Importantly, the righting reﬂex of DDD mice
was normal at all time periods analyzed (Figure 3I), indicating
that this akinesia is not related to global sedation but rather
to deﬁcient movement control. It should be noted also that
this global phenotype, which might be viewed as ‘‘freezing,’’
can be on some occasions temporarily disrupted by an acous-
tic startle or other stressful stimulus. However, after man-
ifesting a few movements, the animals return to an akinetic
state (data not shown). Strikingly, DDD mice, when placed in
water, were able to swim with periods of ﬂoating and active
swimming for at least a 3-min period (see Video S1),
indicating that under certain conditions, movement can
occur essentially without DA. Finally, in agreement with
neurochemical data (see Figure 1B), the recovery from this
profound akinetic phenotype in DDD mice occurs approx-
Figure 2. Display of Behavioral Phenotypes of DDD Mice
(A) Akinesia and rigidity of DDD mice. Photos were taken 30 min after
treatment of DAT-KO mice with aMT (250 mg/kg IP).
(B) Ptosis in DDD mice. Photos were taken 3 h after treatment of DAT-KO
mice with aMT (250 mg/kg IP). Lower panel: Mouse on the left side is
saline-treated DAT-KO mouse, whereas the mouse on the right side is
aMT-treated DAT-KO mouse.
DOI: 10.1371/journal.pbio.0030271.g002
Figure 3. aMT-Induced Impairment in Motor Control in DAT-KO Mice
Dynamics of locomotor activity following systemic administration of aMT
(250 mg/kg IP) and saline (30 min after placement in the locomotor
activity chamber) in WT (A) and DAT-KO (B) mice (n ¼ 6–8 per group).
Analysis of total distance traveled for 210 min after drug administration
revealed significant effect of aMT treatment (p , 0.05; Student’s t-test)
in DAT-KO but not WT mice (WT-saline, 516 6 50 cm/210 min; WT-aMT,
505 6 98 cm/210 min; DAT-KO–saline, 18,489 6 4,795 cm/210 min; DAT-
KO–aMT, 448 6 75 cm/210 min). aMT (injected at time 0) induced
profound alterations in the akinesia (C), catalepsy (D), grasping (E),
bracing (F) tremor (G), and ptosis (H) tests, but did not affect the righting
reflex (I) in DAT-KO mice. Behavioral tests were performed as described
in Materials and Methods. At all the time points, DAT-KO mice were
significantly different versus respective values (data not shown) of saline-
treated DAT-KO controls (p , 0.05; Student’s t-test n ¼ 6 per group) in
these tests with exception of 15-min time point for ptosis (H) and all time
points for righting reflex test (I). In WT mice only the akinesia test (C)
revealed minor, yet significant, effect (1.5–4 h after aMT treatment)
versus values (data not shown) of the respective saline treated WT
controls (p , 0.05; Student’s t-test; n ¼ 6 per group). No significant
alterations in any other test at any time point examined (D–I) was noted
in aMT-treated versus saline treated (data not shown) WT mice.
Locomotor activity is restored in DAT-KO mice 16–24h after aMT (250
mg/kg IP) treatment (J).
DOI: 10.1371/journal.pbio.0030271.g003
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recovery of animals allows repeated treatment with aMT,
and, in fact, DAT-KO mice chronically treated with aMT
(100 mg/kg, IP, once every 3 d) for a period of 40 wk showed
no negative consequences [60].
L-DOPA and Nonselective DA Agonists Restore Motor
Activity in DDD Mice
The locomotor restoring effects exhibited by L-DOPA and
DA agonists in various models of DA deﬁciency form one of
the best-established paradigms in neuroscience [3,15,45,61].
As expected, high doses of L-DOPAalone (Figure 4A), orlower
doses of L-DOPA given along with carbidopa (Figure 4B–4D)
to reduce its peripheral metabolism via L-AADC inhibition,
effectively restore locomotion in DDD mice. In fact, these
treatments temporarily restore locomotion to the levels
observed in untreated DAT-KO mice (Figure 4A–4D), which
are normally at least 10 times more active than WT mice when
placed into a novel environment [11,13]. Other manifestations
associated with DA deﬁciency as described in Figure 3 were
also essentially completely reversed (data not shown).
Efﬁcacy of exogenous direct DA agonists was also tested in
this model. Although the nonselective D1/D2 DA receptor
agonists apomorphine and pergolide were somewhat effective
in inducing forward locomotion (Figure 4E and 4F), the
activity levels of DDD mice following these treatments were
substantially lower than those induced by L-DOPA. Strik-
ingly, the selective D1 DA receptor agonist (þ)-SKF81297 and
D2 DA receptor agonists, bromocriptine and quinpirole, were
ineffective in inducing forward locomotion when adminis-
tered separately (Figure 4G–4I). However, the combined
administration of the D1 and D2 agonists (þ)-SKF81297 plus
quinpirole restored movement and induced forward loco-
motion (Figure 4J), supporting the well-established coopera-
tive interaction of D1 and D2-like DA receptors in locomotor
activity [62].
Movement-Restoring Actions of Amphetamine Derivatives
in DDD Mice
The loss of DA signaling that creates the motor symptoms
of PD occurs upstream of many nondopaminergic pathways.
This suggests that activation or inhibition of some of these
downstream neuronal circuits could potentially reverse the
motor deﬁcits independent of restoration of DA activity. We,
therefore, tested several non-dopaminergic compounds that
potentially could reverse the consequences of severe DA
deﬁciency in DDD mice (see Table 1). Many of these
compounds have been found to be effective in restoring
some aspects of movement control in one or another
experimental animal model of PD and/or in PD patients
[21,26,27,48,49]. However, in DDD mice none of the drugs
were effective in restoring the major aspects of movement
control required for forward locomotion (distance traveled).
Although it is likely that the lack of locomotor effects of these
drugs in DDD mice is related to an unprecedented level of DA
depletion in these mice, it should be emphasized that in our
studies only a few doses or combinations of drugs were tested.
Furthermore, several treatments, although not inducing
forward locomotion per se, were, nevertheless, somewhat
effective in reversing other manifestations of DA deﬁciency.
For example, the NMDA receptor antagonist MK-801 was
able to reduce rigidity and promote weak, disorganized
Figure 4. L-DOPA and Nonselective DA Agonists Are Effective in
Restoring Locomotion in DDD Mice
DAT-KO mice were placed in the locomotor activity chamber and 30 min
later were treated with aMT (250 mg/kg IP) and 1 h after aMT were
challenged with single or multiple doses of a drug (interval between
treatments is 1 h). L-DOPA itself (A) or in combination with carbidopa (B–
D) effectively restored locomotion in DDD mice, as revealed by the
significant effect of L-DOPA at doses 100 and 200 mg/kg IP, or
combinations of L-DOPA/carbidopa at doses 20/20, 50/20, and 50/50
mg/kg, IP (analysis of total distance traveled for 1 h after each dose of
the drug; p , 0.05, two-tailed Mann-Whitney U test versus respective
values in saline-treated DDD mice; data not shown). Nonselective DA
receptor agonists, apomorphine (E) at doses 2 and 3 mg/kg SC, and
pergolide (F) at doses 5, 10, and 20 mg/kg IP, induced locomotion in
DDD mice (analysis of total distance traveled for 1 h after each dose of
the drug; p , 0.05, two-tailed Mann-Whitney U test, versus respective
values in saline-treated DDD mice; data not shown). D2 DA receptor
agonists bromocriptine (G), quinpirole (H), and D1 DA receptor agonist
(þ)-SKF81297 (I) were not effective, but the combinations of D1 and D2
DA agonists (þ)-SKF81297 plus quinpirole at doses 5/1 and 10/5 mg/kg
IP, induced significant locomotion in DDD mice (analysis of total distance
traveled for 1 h after each treatment; p , 0.05, two-tailed Mann-Whitney
U test versus respective values in saline-treated DDD mice; data not
shown). Experiments were performed in 6–12 mice per group.
DOI: 10.1371/journal.pbio.0030271.g004
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Drug Class Drug Doses (mg/kg) Number of Mice
Glutamate receptor antagonists NMDA receptor antagonist (þ)-MK-801 0.1 (IP) 4
0.3 (IP) 6
1 (IP) 6
1.5 (IP) 5
2 (IP) 6
3 (IP) 5
(þ)-MK-801 plus 5HT1B agonist RU24969 1/2, 2/5, and 5/10 (IP) 4
(þ)-MK-801 plus Clonidine 2/0.5 and 1 (IP) 4
Clonidine plus (þ)-MK-801 0.2, 0.8, and 2/0.2 (IP) 4
Muscarinic drugs Atropine 20, 50, and 100 (IP) 4
Clonidine plus Atropine 0.2, 0.8, and 2/40 (SC/IP) 4
MAO inhibitors Deprenyl 5, 10, and 20 mg/kg (IP) 4
Pargyline 20 and 40 mg/kg (IP) 5
A2 adenosine receptor antagonists 8-(3-Chlorostyryl)caffeine (CSC) 5, 10, and 20 (IP) 4
Caffeine 10, 20, and 30 (IP) 4
Serotonin releasers 5-Methoxy-N,N-dimethyltryptamine 10, 10, and 20 (IP) 4
5-Methyl-N,N-dimethyltryptamine 10, 20, and 50 (IP) 4
a-Ethyltryptamine 10, 30, and 60 (IP) 8
Serotonergic drugs 5-HT1B receptor agonist RU24969 5 (IP) 4
Methysergide 5, 10, and 20 (IP) 4
Fluoxetine 10, 20, and 40 (IP) 4
Adrenergic drugs NE precursor L-DOPS 100, 200, and 400 (IP) 4
Desipramine 10, 20, and 40 (IP) 4
Phentolamine 6 (IP) 4
Clonidine 0.2 and 0.8 (IP) 4
Trace amines p-Tyramine 50, 100, and 200 (IP) 4
Deprenyl plus p-Tyramine 5/50, 5/100, and 5/200 (IP) 4
20/50, 100, and 200 (IP) 4
m-Tyramine 50, 100, and 200 (IP) 4
Pargyline plus m-Tyramine 20/200 (IP) 4
Octopamine 50, 100, and 150 (IP) 4
Deprenyl plus Octopamine 5/50, 5/100, and 5/150 (IP) 4
Pargyline plus L-Tyrosine 75/50, 100, and 150 (IP) 4
Tryptamine 150, 200, and 300 (IP) 4
Pargyline plus Tryptamine 20/50, 100, and 200 (IP) 4
b-Phenylethylamine 20, 50, and 200 (IP) 4
30, 60, and 90 (IP) 5
Deprenyl plus b-Phenylethylamine 5/50, 5/100, and 5/200 (IP) 4
20/50, 100, and 200 (IP) 4
Amphetamines d-Amphetamine 10, 15, and 20 (IP) 8
40 and 40 (IP) 8
50 and 50 (IP) 7
60 and 60 (IP) 4
Methamphetamine 5, 10, and 15 (IP) 8
30 and 50 (IP) 6
30, 30, and 90 (IP) 6
Methamphetamine plus Methysergide 60/20 (IP) 4
4-Chloro-amphetamine 30 and 60 (IP) 8
Phentermine 10, 30, and 50 (IP) 6
75 (IP) 4
Phentermine plus Methysergide 50/5 (IP) 8
(6)-MDE 30 and 60 (IP) 6
(þ)-MDE 30 and 60 (IP) 6
( )-MDE 30 and 60 (IP) 6
(6)-MDA 30 and 60 (IP) 16
90 (IP) 8
(6)-6-OH-MDA 30 and 60 (IP) 6
(6)-MDMA 10, 30, and 40 (IP) 7
80 (IP) 8
(þ)-MDMA 1, 3, and 10 (IP) 8
30 and 30 (IP) 6
Drugs (or combinations of drugs) were administered 1 h after aMT treatment (250 mg/kg IP). In cumulative dosing experiments, animals were treated with drugs after a 1-h interval.
DOI: 10.1371/journal.pbio.0030271.t001
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increase in forward locomotion (Table 1). Synthetic amino
acid L-DOPS (L-threo-3,4-dihydroxyphenylserine), which is
decarboxylated to NE by L-AADC, selectively reversed ptosis
in DDD mice. Cumulative dosing experiments revealed ptosis
scores (measured 1h after each treatment) of 2.50 6 0.28 after
100 mg/kg, 0 after 200 mg/kg, and 0 after 400 mg/kg IP of L-
DOPS (n¼4), whereas corresponding values for saline-treated
controls (n ¼ 6) were 3.3 6 0.3, 3.7 6 0.2, and 3.7 6 0.2,
respectively. Effects of 200 and 400 mg/kg of L-DOPS on
ptosis in DDD mice were signiﬁcantly different as compared
to respective control values (p , 0.05, Student’s t-test)
supporting an important role of NE in this behavioral
manifestation [59]. Similarly, high doses of the trace amine
b-phenylethylamine [44,63] (with or without concomitant
inhibition of MAO) did not induce forward locomotion, but
did promote weak stereotypic reactions, such as head-
weaving and snifﬁng (data not shown). Further investigations
will be required to fully evaluate the efﬁcacy of these drugs in
DDD mice.
Unexpectedly, this initial screening revealed a potent
effect of amphetamine derivatives on behavioral manifes-
tations of DDD mice. High doses of d-amphetamine, d-
methamphetamine, 4-chloro-amphetamine, phentermine,
(6)-MDE ((6)-N-ethyl-3,4-methylenedioxyamphetamine HCl),
(þ)-MDE ((þ)-N-ethyl-3,4-methylenedioxyamphetamine HCl),
( )-MDE (( )-N-ethyl-3,4-methylenedioxyamphetamine HCl),
(6)-MDA ((6)-3,4-methylenedioxyamphetamine HCl), (6)-6-
OH-MDA ((6)-6-hydroxy-3,4-methylenedioxyamphetamine
HCl), (6)-MDMA ((6)-3,4-methylenedioxymethamphetamine
HCl), and (þ)-MDMA ((þ)-3,4-methylenedioxymethamphet-
amine HCl) were effective in reducing manifestations of
akinesia and rigidity in DDD mice as detected in the
catalepsy, grasping, and akinesia tests (Figure 5A–5C).
However none of these drugs (with the exception of (þ)-
Figure 5. Amphetamine Derivatives at High Doses Are Effective in Reversing Abnormal Motor Behaviors of DDD Mice
DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with aMT (250 mg/kg IP), and 1 h after aMT were challenged
with single or multiple doses of drugs (in cumulative dosing experiments, the interval between treatments was 1 h). Grasping (A), catalepsy (B), and
akinesia (C) tests were performed as described in Materials and Methods 1 h after each dose (the only exception is (6)-MDMA at 80 mg/kg IP where
measurements were performed 2 h after the drug administration). An asterisk indicates p , 0.05 versus respective values of saline-treated DDD mice
(one-way ANOVA followed by Dunnet’s multiple comparison test). Experiments were performed in 6–16 mice per group. d-AMPH indicates d-
amphetamine; METH, d-methamphetamine; and 4-chloro-AMPH, 4-chloro-amphetamine.
DOI: 10.1371/journal.pbio.0030271.g005
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Acute Mouse Model of Parkinson DiseaseMDMA, see below) was effective in restoring movement
control sufﬁciently to induce forward locomotion (Table 1).
DA-Independent Locomotor Effects of (þ)-MDMA
in DDD Mice
Among amphetamine derivatives, the most effective com-
pound to counteract manifestations of akinesia and rigidity in
DDD mice was (þ)-MDMA (Figure 5A–5C). Thus, we tested (þ)-
MDMA in locomotor assay at even higher doses than those
indicatedinTable1.AspresentedinFigure6A–6C,(þ)-MDMA
at high doses was able to induce signiﬁcant forward locomo-
tion in DDD mice as measured by distance traveled in a
locomotor activity test. This locomotor action of (þ)-MDMA
was observed in both cumulative (Figure 6A) and single dose
(Figure 6B and 6C) treatments. In cumulative dosing experi-
ments, a ﬁrst treatment with 30 mg/kg of (þ)-MDMA was not
effective, but the subsequent administration of 60 mg/kg
induced signiﬁcant forward locomotion (Figure 6A) as well as
reversal of other behavioral manifestations (see Figure 5A–5C)
in DDD mice. Finally, testing of various single doses clearly
showed a dose-dependence of the locomotor effect of (þ)-
MDMA in DDD mice (Figure 6C).
The locomotor stimulating effect of amphetamine and its
derivatives are classically thought to result from the massive
efﬂux of DA from presynaptic DA terminals via a mechanism
including displacement of DA from vesicular storage and
reversal of DAT-mediated DA transport [7,38–40]. However,
in DDD mice, there is only a minimal amount of DA
remaining (,0.2%) and the lack of the DAT precludes the
possibility of amphetamine-mediated DA efﬂux. In fact, in
vivo microdialysis studies conﬁrmed that (þ)-MDMA, at the
effective dose necessary to induce signiﬁcant locomotor acti-
vation in DDD mice, did not produce any detectable increase
in striatal extracellular DA (Figure 6D). Moreover, this loco-
motor stimulation by (þ)-MDMA was not inhibited by simul-
taneous blockade of D1/D2 DA receptors when DDD mice
were pretreated with a combination of the D1 and D2 DA
receptor antagonists, SCH23390 and raclopride (Figure 6C).
Similarly, this pretreatment did not prevent the effects of
amphetamine and phentermine on the akinesia and rigidity
in DDD mice in grasping and akinesia tests (see Figure S1). In
contrast, the same D1/D2 DA receptor blockade completely
abolished the locomotor stimulating effects of L-DOPA/
carbidopa (50/50 mg/kg IP) in DDD mice (see Figure S2).
Taken together, these data indicate that (þ)-MDMA can affect
movement control in a DA-independent manner [64] and,
most importantly, provide a proof-of-principle that pharma-
cologic activation of nondopaminergic neuronal pathways
may be sufﬁcient to restore movement even in the absence of
DA neurotransmission.
It should be noted that the locomotor-stimulating effect of
(þ)-MDMA in DDD mice was observed only after high doses of
the drug, which may be potentially neurotoxic [38]. However,
the lack of the DAT renders dopaminergic neurons in DAT-
KO mice signiﬁcantly less sensitive to the neurotoxic effects
of amphetamines, such as methamphetamine [65], as well as
to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
[66,67]; thereby providing a unique opportunity to evaluate
effects to large doses of amphetamines that would be im-
possible in normal animals [38]. It should be mentioned also
that mice are generally less sensitive to MDMA neurotoxicity,
particularly with regards to the serotonergic system [68].
Figure 6. (þ)-MDMA Induces Forward Locomotion in DDD Mice
(A–C) DAT-KO mice were placed in the locomotor activity chamber and
30 min later were treated with aMT (250 mg/kg IP) and 1 h after aMT
were challenged with single (B and C) or multiple doses (A) of a drug
(interval between treatments is 1 h) (n ¼ 10–16 per group). Repeated
treatment with (þ)-MDMA (30 and 60 mg/kg IP) induces forward
locomotion in DDD mice (A). Analysis of total distance traveled for 1 h
after 60 mg/kg IP of (þ)-MDMA reveals significant effect of treatment
versus respective period in saline-treated controls (p,0.05, two-tailed
Mann-Whitney U test, data not shown). Dynamics (B) and dose-response
(C) of locomotor effect of (þ)-MDMA in DDD mice are shown.
Pretreatment with D1 and D2 DA antagonists (SCH23390, 0.1 mg/kg
SC plus raclopride, 2 mg/kg IP) 30 min before 100 mg/kg IP (þ)-MDMA)
did not affect locomotor action of (þ)-MDMA (C).
(D) (þ)-MDMA (100 mg/kg IP) fails to affect DA dynamics in the striatum
of DDD mice as measured by in vivo microdialysis. Data are presented as
a percentage of the average level of DA measured in at least three
samples collected before aMT administration (n ¼ 4). Analysis of area
under curve values for 120-min periods after (þ)-MDMA administration
revealed no significant difference in comparison with respective values in
control group (Figure 1F; p . 0.05, two-tailed Mann-Whitney U test).
(E and F) (þ)-MDMA (E) as well as d-amphetamine and d-methamphet-
amine (F) at moderate doses potentiate locomotor-stimulating effect of
subthreshold dose of L-DOPA/carbidopa (10/10 mg/kg IP). DAT-KO mice
were treated with aMT as described above (A–C) and 45 min after aMT
were injected with amphetamines. L-DOPA/carbidopa was injected
15 min after amphetamines, and distance traveled for 2h was measured
(n ¼ 6–15 per group). Note, that no forward locomotion was observed
afterthesedosesof(þ)-MDMA,d-amphetamineandd-methamphetamine
without L-DOPA/carbidopa, whereas L-DOPA/carbidopa (presented as
drug dose 0) induced only a modest but significant (p , 0.05) increase in
locomotion over saline-treated controls (data not shown).
Single asterisk indicates p , 0.05; double asterisks indicate p , 0.01;
and triple asterisks indicate p , 0.001 versus saline-treated controls (C)
or L-DOPA/carbidopa-treated (10/10 mg/kg IP) group (E and F) (two-
tailed Mann-Whitney U test). d-AMPH, d-amphetamine; METH,
d-methamphetamine.
DOI: 10.1371/journal.pbio.0030271.g006
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MDMA in DAT-KO mice, we treated DAT-KO and WT mice
with an established neurotoxic regimen of (6)-MDMA admin-
istration (4 injections of 20 mg/kg IP, every 2 h) [69] and
assessed striatal tissue DA and 5-HT levels 7 d later. As might
be expected, no signiﬁcant differences in both DA and 5-HT
levels were found between (6)-MDMA-treated and saline-
treated DAT-KO mice (saline-treated DAT-KO mice (n ¼ 6):
DA, 0.53 6 0.03 ng/mg tissue; 5-HT, 0.36 6 0.03 ng/mg
tissue; (6)-MDMA-treated DAT-KO mice (n ¼ 7): DA, 0.58 6
0.04 ng/mg tissue; 5-HT, 0.40 6 0.02 ng/mg tissue), whereas
the same regimen of treatment resulted in lethality of all
treated WT mice (n ¼ 7).
Furthermore, to test whether the locomotor-stimulating
effect of (þ)-MDMA may be evident under certain conditions
with lower (nonneurotoxic) doses of the drug, we co-
administered (þ)-MDMA with a minimally effective dose of
L-DOPA/carbidopa (10/10 mg/kg, IP.). As shown in Figure 6E,
a potent synergistic effect of L-DOPA/carbidopa and (þ)-
MDMA was observed. Furthermore, similar effects were
observed with relatively moderate doses of d-amphetamine
and d-methamphetamine (Figure 6F). Thus, a DA-independ-
ent locomotor effect of amphetamines can be markedly
enhanced with additional dopaminergic stimulation. It is also
important to note that in a similar experiment, MAO
inhibitor deprenyl (5, 10, or 20 mg/kg IP) failed to potentiate
the effects of L-DOPA/carbidopa (data not shown), indicating
that this effect is not related to the well-known MAO-
inhibiting action of amphetamines [38].
Nomifensine, but Not GBR12909 Affects Rigidity
and Akinesia in DDD Mice
Finally, to evaluate the potential of other TA1 receptor
ligands for their ability to affect motor control in DDD mice,
we elected to compare the effects of two potent DAT blockers
that have been shown to be markedly different with regards
to their activity at TA1 receptor. It has been recently
reported that the mixed DAT and NET inhibitor nomifensine
can also potently activate TA1 receptor whereas the selective
DAT blocker GBR12909 completely lacks the ability to
interact with TA1 receptor [42]. In DDD mice, both
nomifensine and GBR12909 at doses tested (cumulative
treatment with 10 and 30 mg/kg IP) were not effective in
inducing forward locomotion or reversing catalepsy (data not
shown). Nevertheless, nomifensine signiﬁcantly reduced
akinesia and rigidity in grasping and akinesia tests
(Figure 7A and 7B), whereas no such effects were observed
with equivalent doses of GBR12909 (Figure 7A and 7B).
Discussion
In this study we demonstrate that inhibition of DA
synthesis in DAT-KO mice represents a straightforward
approach for developing an acute model of severe DA
deﬁciency exhibiting a characteristic behavioral phenotype
that can be utilized for testing perspective anti-PD treat-
ments. Furthermore, these observations provide functional
evidence for an important role of DAT-mediated recycling
mechanism in the maintenance of intraneuronal DA. Finally,
the novel DAT- and DA-independent locomotor action of
amphetamines identiﬁed in these mice directly demon-
strates the possibility of movement in a DA-independent
manner.
Role of DAT-Mediated DA Recycling in the Maintenance
of Intraneuronal DA Storage
DAT is commonly known as a major regulator of the
duration and intensity of extracellular DA signaling. However
the important role of DAT in the control and maintenance of
the intraneuronal DA storage pool frequently remains over-
looked. It is generally assumed that the intraneuronal storage
of DA is replenished primarily from newly synthesized DA
with some contribution from recycled DA. However, several
lines of evidence support a predominant role of DAT-
mediated recycling of DA for the maintenance of the large
storage pool in DA terminals. First, mice lacking the DAT
display dramatically decreased (20-fold) striatal tissue DA
content, that mostly represents intraneuronal DA concen-
trations. Second, as we demonstrate in the present study, the
remaining DA in all compartments is extremely sensitive to
TH inhibition. Furthermore, pharmacologic studies have
s h o w nt h a ts i g n i ﬁ c a n tD Ad e p l e t i o nm a yo c c u ra f t e r
administration of DAT inhibitors, particularly after chronic
drug treatment [13]. Importantly, in the frontal cortex, where
DAT levels are normally low in comparison to the striatum,
tissue DA concentration is also low and can be more
signiﬁcantly affected than in the striatum by aMT [70]. It is
likely that the newly synthesized DA does not contribute
directly to the large storage pool of DA in nigrostriatal
terminals, but rather contributes to it indirectly via released
and recycled DA. Thus, a cooperative function of both DA
synthesis and transporter-mediated recycling processes is
necessary for the maintenance of normal presynaptic mono-
amine concentrations.
Figure 7. Nomifensine, but Not GBR12909, Is Effective in Reversing
Abnormal Motor Behaviors of DDD Mice
DAT-KO mice were placed in the locomotor activity chamber and 30 min
later were treated with aMT (250 mg/kg IP). Mice were challenged 1 h
later with two doses (10 and 30 mg/kg IP) of each drug or saline with a
1 h interval between treatments (n ¼ 9–15 per group). Grasping (A) and
akinesia (B) tests were performed as described in Materials and Methods
1 h after each dose. A single asterisk indicates p , 0.05, double asterisks
indicate p , 0.01, and triple asterisks indicate p , 0.001 versus
respective values of saline-treated DDD mice (one-way ANOVA followed
by Dunnet’s multiple comparison test). Note that no significant
differences between GBR12909-treated mice and saline-treated controls
in both tests were found, whereas nomifensine-treated mice were
significantly different from GBR12909-treated mice (p , 0.05) in both
experimental paradigms and doses tested.
DOI: 10.1371/journal.pbio.0030271.g007
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DA-Depleted DAT-KO (DDD) Mice
By using a combination of genetic and pharmacologic ap-
proaches we have developed a novel acute mouse model of
severe DA deﬁciency, DDD mice. The lack of an active
recycling mechanism in DAT-KO mice results in a profound
depletion of intraneuronal concentrations of DA leaving the
remaining DA entirely dependent on ongoing synthesis. As a
result, inhibition of DA synthesis essentially eliminates
striatal DA in these mice leading to the extreme behavioral
manifestations. In fact, DDD mice demonstrate a unique set
of behaviors that reproduces symptoms of PD with high
ﬁdelity. Thus, the lack of DA combined with the striking and
highly reproducible behavioral phenotype in these mice can
be used as an excellent tool to evaluate the potential of drugs
that can affect locomotion in a DA-independent manner.
Furthermore, by adapting the dose of aMT to produce
various degrees of DA depletion, these mice can also be
employed to ﬁnd novel approaches to restore movement
under conditions of partially impaired DA transmission that
might be more relevant to most PD cases.
Several rodent models have been developed to understand
pathological processes leading to PD and/or to screen for
novel therapeutic strategies [29,30,34 36,71]. These models
either recapitulate the loss of DA through pharmacologic or
genetic manipulation, or recapitulate the neurodegenerative
process through administration of selective neurotoxins and,
recently, through mutations of speciﬁc proteins. However, in
many of these models only incomplete and highly variable
levels of DA depletion are achieved often precluding an
accurate recapitulation of the neurological manifestations of
PD. This poor behavioral expression of PD-related behaviors
generally results in high level of false-positive results in drug
screening tests in general, and particularly in those attempted
to identify non-DA therapies [72].
Among several genetic mouse models of DA deﬁciency
available today [73,74], the most effective was developed by
inactivation of TH in DA neurons (DA-deﬁcient [DD mice])
[3,75–81]. DD mice have provided important insights into the
role of DA in movement control, feeding, and reward. This
mutation results in severely impaired movement and feeding,
which become apparent at 10 d and leads to death by 30 d. To
maintainviablemicewiththeabilitytomoveandfeedrequires
dailytreatmentwithL-DOPA,whichresultsinanoscillationof
striatal DA from about 1% to 10% over 24 h [77,81]. Many
behavioral manifestations observed in DDD mice in this study,
such as rigidity and akinesia, were observed previously in DD
mice [3,76,79]. Importantly, both of these models showed
temporal locomotor reactivity to stress and demonstrated
normal righting reﬂex and ability to swim, indicating that
certain movements may occur in a DA-independent manner.
Despite these similarities, some important differences were
noted between these two genetic models of severe DA
dysfunction. In DD mutant mice, a lack of TH resulting in
permanently decreased DA signaling, as well as daily treat-
ments with L-DOPA render these mice extremely super-
sensitive to DA stimulations [81], whereas excessive DA
signaling in DAT-KO mice results in compensatory down-
regulation (but nonuniform) of DA receptors [11,13]. This may
explainwhycertainbehavioralmanifestationsofDAdeﬁciency
such as rigidity and akinesia may be more robust in DDD mice,
whereas tremor was not observed in DD mutants [3,76]. Fur-
thermore,efﬁcacyof L-DOPAandDA agonistsareremarkably
higher in DD in comparison to DDD mice [3,76,81]. Addition-
ally, several other drugs, such as caffeine and N-methyl-D-
aspartate receptor antagonist MK-801, that are able to induce
locomotion in DD mutants [75,80] are not effective in DDD
mice (Table 1). In fact, down-regulation of DA receptor
responsiveness combined with the extreme level of DA deple-
tion in DDD mice may favor these mice as a very conservative
approach for evaluating drugs that can affect locomotion in a
DA-independent manner. Furthermore, rapid and effective
elimination of DA in DDD mice may provide a simple in vivo
approach to study DA receptor signaling [82] and/or to deﬁne
neuronal circuitry involved in locomotor control [83].
DA-Independent Locomotor Action of Amphetamines
Intriguingly, in both DD and DDD mice d-amphetamine
was effective in restoring at least some aspects of locomotor
behaviors. In DD mice, d-amphetamine (5 mg/kg IP) induced
potent locomotor activation essentially up to the levels
observed in WT controls. At the same time, a second
treatment 2 h later by the same dose of the drug failed to
induce locomotion in DD mice suggesting that this effect is
dependent upon residual (after L-DOPA administration) DA
which might be depleted by the ﬁrst treatment with the drug
[76]. In DDD mice, d-amphetamine itself was not able to
induce forward locomotion at doses up to 60 mg/kg, but it
produced signiﬁcant effects on other manifestations of DA
deﬁciency. Moreover, co-administration of relatively moder-
ate doses of amphetamine (15 and 20 mg/kg) with a
subthreshold dose of L-DOPA resulted in a marked locomo-
tor activation of DDD mice. Thus, some DA tone seems to be
necessary to express the full magnitude of locomotor
activation by amphetamine, but it is evident that there is a
DA-independent component of action that contributes to the
overall effect of the drug. Further evidence for this idea
relates to the fact that many other amphetamine derivatives
are also active in reversing certain behavioral manifestations
in DDD mice. Strikingly, both single and repeated treatment
with (þ)-MDMA was effective in inducing forward locomotion
essentially without any contribution of DA. It is important to
note that a potent anticataleptic effect of MDMA in
haloperidol-treated rats [84] and antiakinetic effects in 6-
OH-DA–lesioned rats [85] and MPTP-treated monkeys [64]
have been recently reported. The present observations
support these ﬁndings and suggest that these actions are
not unique to MDMA but may be extended to other
amphetamines. Further characterization of these unexpected
effects of amphetamines may provide a novel framework in
the search for potential anti-Parkinsonian drugs.
Amphetamine derivatives are known mainly as indirect
enhancers of monoaminergic (DA, NE, and 5-HT) trans-
mission via complex interactions with the plasma membrane
monoamine transporters and the vesicular storage of these
monoamines [7,10,12,38,39]. It should be reiterated that a lack
of DAT in DAT-KO mice excludes the possibility of major
effects of amphetamines on DAT-mediated DA efﬂux from
presynaptic DA stores [40]. Furthermore, a blockade of D1/D2
DA receptors was ineffective in preventing the locomotor
stimulating action of (þ)-MDMA. Thus, it is virtually impos-
sible that the observed effects of MDMA and other amphet-
amines in DDD mice are directly related to DA transmission.
Although it is possible that this effect may be due to
PLoS Biology | www.plosbiology.org August 2005 | Volume 3 | Issue 8 | e271 1497
Acute Mouse Model of Parkinson Diseasetransporter-mediated action of amphetamines on NE or 5-HT
transmission [38,40,86], it should be noted that among several
NE- and 5-HT–related drugs tested (desipramine, clonidine,
the NE precursor DOPS, ﬂuoxetine, 5-methoxy-N,N-dime-
thyltryptamine, 5-methyl-N,N-dimethyltryptamine, a-ethyl-
tryptamine, and 5-HT1B agonist RU24969), none were
effective in DDD mice in tests of forward locomotion or
akinesia and rigidity (data not shown). Similarly, no locomotor
effect of MAO-A or MAO-B inhibitors was observed in these
mice, indicating that the locomotor effect of amphetamines
may not be explained by MAO-inhibitory action [38].
Furthermore, it should be underlined that locomotor actions
of amphetamines observed in DDD mice occur at doses that
are much higher than necessary to induce classic transporter-
mediated effects [10,38,83].
Amphetamines share close structural similarity with an
endogenous trace amine of unknown function b-phenylethyl-
amine [87]. Amphetamines and b-phenylethylamine similarly
interact with the plasma membrane monoamine transporters
to elevate extracellular monoamine concentrations [63].
Intriguingly, recent evidence indicates that many amphet-
amine derivatives, including MDMA, may also act directly as
agonists of trace amine TA1 receptors, that are known to be
activated by b-phenylethylamine [42,88]. Several members of
the family of trace amine receptors have been identiﬁed,
howeverlittleisknownaboutthepharmacologyandfunctional
roleofthesereceptorsinmammalianphysiology[43,44,63].Itis
reasonable to suggest that activation of TA1 receptors [42] or
other trace amine receptors may provide a potential mecha-
nism for DA-independent locomotor effect of MDMA and
amphetamines in DDD mice. In line with this hypothesis, we
observed that the DAT blocker nomifensine that can activate
TA1 receptor, but not GBR12909 which is devoid this activity
[42], is able to affect motor control in DDD mice. It should be
noted,however,thatinourinitialexplorationinDDDmice,we
did not observe clear locomotor effects for any trace amine
tested;butonlyafewdoses,routesofadministration,andcom-
binations with enzyme inhibitors were investigated. Further
detailedinvestigations willbe neededtoclarifythemechanism
of locomotor action of amphetamines in DDD mice.
Conclusions
In summary, these results provide additional functional
evidence for the critical role of DAT in the maintenance of
DA storage in presynaptic terminals. Rapid and effective
abolishment of DA by inhibition of DA synthesis in DAT-KO
mice provides a novel approach to develop severe DA
deﬁciency that might be used to identify neuronal mecha-
nisms involved in motor control in the absence of DA.
Amphetamines are capable of affecting neuronal systems
involved in motor control through mechanisms independent
of DAT, in particular, and DA in general.
Materials and Methods
Animals. DAT-KOmiceweregeneratedaspreviouslydescribed[11].
Animal care was in accordance with the Guide for Care and Use of
Laboratory Animals (National Institutes of Health publication #865–
23,Bethesda,Maryland,UnitedStates)withanapprovedprotocolfrom
the Duke University Institutional Animal Care and Use Committee.
C57BL/6J3129Sv/J hybrid WT and DAT-KO mice, 3–5 mo old, of both
sexes were used. None of animals used in these studies had the neuro-
degenerative phenotype sporadically observed in DAT-KO mice [60].
Drugs. Drugs or saline (0.9% NaCl) were administered intra-
peritoneally (IP) or subcutaneously (SC) in a volume of 10 ml/kg. The
drugs were either from Sigma (St. Louis, Missouri, United States) or
supplied by the National Institute of Drug Abuse (NIDA). Drugs
provided by the NIDA Drug Supply Program included: (6)-MDMA,
(þ)-MDMA, (6)-6-OH-MDA, (6)-MDA, (6)-MDE, (þ)-MDE, ( )-MDE,
and AET (a-ethyl-tryptamine acetate).
Neurochemical assessments. Striatal tissue contents of DA and
frontal cortical tissue levels of NE were assessed using HPLC-EC (high
performance liquid chromatography with electrochemical detection)
as described [8]. In vivo microdialysis measurements of striatal
extracellular DA levels in freely moving mice were performed at least
24 h after implantation of a microdialysis probe as described pre-
viously [50]. Dialysate samples were assayed for DA using HPLC-EC.
Behavioral methods. LocomotoractivityoflittermateWTandDAT-
KO mice was measured in an Omnitech CCDigiscan (Accuscan Instru-
ments, Columbus, Ohio United States) activity monitor under bright
illumination[83].Allbehavioralexperimentswereperformedbetween
10:00 AM and 5:00 PM. Activity was measured at 5-min intervals. To
evaluatetheeffectsofdrugsonmotorbehaviors,micewereplacedinto
activity monitor chambers (20 3 20 cm) for 30 min and then treated
withaMT(250mg/kgIP).Adrugorcombinationofdrugswereinjected
1hafteraMTadministration,andvariousparametersoflocomotorac-
tivity were monitored for up to 3 h. In cumulative dosing experiments,
animalsweretreatedwithincreasingdosesofdrugsaftera1-hinterval.
For the akinesia test, the mouse is held by the tail so that it is
standing on forelimbs only and moving on its own. The number of
steps taken with both forelimbs was recorded during a 30-s trial [57].
The presence of catalepsy was determined and measured by placing
the animal’s forepaws on a horizontal wooden bar (0.7 cm in
diameter), 4 cm above the tabletop. The time until the mouse
removed both forepaws from the bar was recorded, with a maximum
cut-off time of 3 min [53]. In the grasping test of muscular rigidity,
the mouse is suspended by its forelimbs on a metal rod (diameter:
0.25 cm) positioned approximately 20 cm above the table. The time
the animal remains on the rod (maximum 1 min) was noted [58]. To
assess rigidity in a bracing task, the number of steps taken with each
forelimb when the mouse is pushed sideways over a distance of 50 cm
was recorded [57]. Tremor was scored visually in mice using the rating
scale [54]: 0, no tremor; 1, occasional isolated twitches; 2, moderate or
intermittent tremor associated with short periods of calm; and 3,
pronounced continuous tremor. Ptosis was scored as described [89]:
4, eyes completely closed; 2, half-open eyes; and 0, wide-open eyes;
with 1 and 3 indicating intermediate values. The righting reﬂex was
evaluated by turning the mouse onto its back ﬁve times. Normal mice
immediately turn themselves over, to right themselves onto all four
feet. Righting reﬂex was scored as follows: 0, no impairment; 1, on
side one to two times; 2, on side three to four times; 3, on side ﬁve
times; 4, on back one to two times; 5, on back three to four times; 6,
on back ﬁve times; 7, sluggish when placed on back; and 8, righting
response absent when on back and tail pinched [55].
Data analysis. The data are presented as mean 6 SEM and
analyzed using a two-tailed Student’s t-test and one-way analysis of
variance (ANOVA) followed by Dunnet’s multiple comparison test or
a two-tailed Mann-Whitney U test when appropriate.
Supporting Information
Figure S1. D1/D2 DA Receptor Blockade Does Not Prevent the Effects
of Amphetamine and Phentermine on Rigidity and Akinesia in DDD
Mice
Found at DOI: 10.1371/journal.pbio.0030271.sg001 (4.8 MB TIF).
Figure S2. D1/D2 DA Receptor Blockade Prevents the Locomotor
Stimulating Effect of L-DOPA/Carbidopa in DDD Mice
Found at DOI: 10.1371/journal.pbio.0030271.sg002 (4.4 MB TIF).
Video S1. Behavioral Phenotype of DDD mice
Found at DOI: 10.1371/journal.pbio.0030271.sv001 (10 MB MOV).
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